Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1276.186 - 1302.655 Dr. Bogdana Schmidt

But certainly, I think we have enough data now that adjuvant therapy in the post-cystectomy setting with nivolumab or pembrolizumab is here, right? So based on this, and obviously I know you have a little bias potentially because it's your data and you're familiar with it. So it's a good bias. If and when both drugs are approved and available in the clinic space, how will you choose between them?